Moraima Trujillo
Psychiatry · Coral Gables, FLNPI 1326130832
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $113,468 of the $121,447 with a category attached, or 93.4%. 13 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 51.3% of the total. Reporting peaked in 2019 at $52,676 and has fallen 99.2% since, to $447 in 2025. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $686.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$62K
- Johnson & Johnson$44K
- Alkermes, Inc.$11K
- Sunovion Pharmaceuticals Inc.$4K
- Indivior Inc.$173
- AbbVie$163
- plus $420 from 7 others
Across 952 payments — averaging $6809.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3.3M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.3M
- Teva Pharmaceuticals USA, Inc.$990K
- E.r. Squibb & Sons, L.L.C.$560K
- Janssen Research & Development, LLC$231K
- Hoffmann-la Roche Limited$60K
- plus $17K from 1 others
What the payments were for
- Speaking & faculty fees$113,46893%
- Travel & lodging$5,8815%
- Food & beverage$2,0752%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 72 | $62,280 |
| Johnson & Johnson | 58 | $43,690 |
| Alkermes, Inc. | 19 | $10,586 |
| Sunovion Pharmaceuticals Inc. | 4 | $4,135 |
| Indivior Inc. | 7 | $173 |
| AbbVie | 3 | $163 |
| Teva Pharmaceuticals USA, Inc. | 2 | $143 |
| E.r. Squibb & Sons, L.L.C. | 5 | $123 |
| Braeburn Inc. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Tempus AI, Inc | 1 | $24 |
| Phadia US Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$61,581
- INVEGA SUSTENNA$24,700
- INVEGA TRINZA$21,965
- SPRAVATO$18,144
- VIVITROL$10,334
- ABILIFY ASIMTUFII$7,644
- LATUDA$4,135
- REXULTI$959
- VRAYLAR$125
- UZEDY$122
How this compares
$121,447 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Zolpidem Tartrate | 13 | $8 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Coral Gables
- Ilan MelnickCoral Gables$2.8M
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.